sucrose has been researched along with ferric oxide, saccharated in 121 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (1.65) | 18.7374 |
| 1990's | 9 (7.44) | 18.2507 |
| 2000's | 33 (27.27) | 29.6817 |
| 2010's | 60 (49.59) | 24.3611 |
| 2020's | 17 (14.05) | 2.80 |
| Authors | Studies |
|---|---|
| Danielson, BG; Derendorf, H; Geisser, P; Salmonson, T | 1 |
| Abbas, M; Abotalib, Z; al-Meshari, A; al-Momen, AK; al-Nuaim, L; Khashogji, T; Saddique, A | 1 |
| Akcicek, F; Atabay, G; Basci, A; Celik, A; Cirit, M; Ok, E; Ozkahya, M; Toz, H; Unsal, A | 1 |
| Bernière, J; Dehullu, JP; Gall, O; Murat, I | 1 |
| Andrade, S; Colaço, S; Oliveira, C; Ponce, P; Santos, JP; Silva, J; Ventura, H | 1 |
| Antoni, G; Beshara, S; Danielson, BG; Långström, B; Lubberink, M; Lundqvist, H; Sundin, J; Tolmachev, V; Valind, S | 2 |
| Atherton, DJ; Cox, I; Hann, I | 1 |
| Asano, T; Baxter, JG; Maebashi, N; Yamaguchi, T | 1 |
| Agbaria, Z; Baruch, R; Blum, M; Deutsch, V; Iaina, A; Irony, M; Schwartz, D; Silverberg, DS; Steinbruch, S; Yachnin, T | 1 |
| Bahner, U; Bettger, H; Kosch, M; Matzkies, F; Schaefer, RM; Teschner, M | 1 |
| Duffy, CI | 1 |
| Baruch, R; Blum, M; Iaina, A; Keren, G; Schwartz, D; Shaked, M; Sheps, D; Silverberg, DS; Steinbruch, S; Tchebiner, J; Wexler, D; Yachnin, T; Zubkov, A | 1 |
| Canziani, ME; Draibe, SA; Manfredi, SR; Neto, MC; Rangel, EB; Yumiya, ST | 1 |
| Chaimovitz, C; Mazor, D; Meyerstein, N; Tovbin, D; Vorobiov, M | 1 |
| Calişkan, S; Camsari, T; Cavdar, C; Celik, A; Onvural, B; Sifil, A; Temiz, A; Yeniçerioğlu, Y | 1 |
| Albarracín, C; Fanlo, B; Junquera, E; Rodríguez Palomares, JR | 1 |
| Kosch, M; Schaefer, RM | 1 |
| Acton, RT; Barton, JC; Coghlan, ME; Ozbirn, TW; Reymann, MT | 1 |
| BUCHI, J; ZOPPI-HUG, R | 1 |
| Borisov, AV; Borisova, EV; Fesiuk, AF; Lovchinskiĭ, EV; Mordik, AI | 1 |
| Chernev, A; Chernev, T; Karag'ozova, Zh; Koleva, R | 1 |
| Anderson, J; Johnson, K; Van Wyck, D | 1 |
| Blum, M; Iaina, A; Schwartz, D; Silverberg, D; Wexler, D | 1 |
| Almer, S; Bodemar, G; Danielson, BG; Kechagias, S | 1 |
| Cuenca Espiérrez, J; García Erce, JA; Martínez Martín, AA; Modrego Aranda, FJ; Solano, VM | 1 |
| Bozhinova, S; Ivanova, I; Lukanova, M | 1 |
| Maslovsky, I | 1 |
| Bailie, GR; Clark, JA; Lane, CE; Lane, PL | 1 |
| Durandy, Y; Hulin, S | 1 |
| Ahlmén, J; Chertow, GM; Mason, PD; Vaage-Nilsen, O | 1 |
| McLoughlin, P; Musthyala, R | 1 |
| Canser, E; Gilsanz, F; Gimeno, M; Gredilla, E; Martínez, B; Pérez Ferrer, A | 1 |
| Gershanovich, ML; Livshits, ME; Makhnova, EV | 1 |
| Juncà, J | 1 |
| Huch, R; Krafft, A; Schaefer, RM | 1 |
| Binder, T; Dvorská, M; Feldmár, P; Záhumenský, J; Zmrhalová, B | 1 |
| Camsari, T; Cavdar, C; Cavdar, Z; Saglam, F; Uysal, S | 1 |
| Boyd, A; Chan, LN; Norenberg, J; Pai, AB; Raj, D | 1 |
| SLACK, HG; WILKINSON, JF | 1 |
| Backe, B; Borthen, I; Kolås, T; Løkvik, B; Nakling, J; Rognerud Jensen, OH; Salvesen, KA; Smedvig, E; Westad, S; Økland, I | 1 |
| Bailey, G; Cropper, L; Mostafa, S; Pugh-Clarke, K; Tagboto, S; Turner, J | 1 |
| Arnaout, L; Bellamy, L; Chabbouh, T; Ozier, Y; Rosencher, N | 1 |
| Chiu, DY; Fenwick, S; Kalra, PA; Kolakkat, S; Lamerton, E; Peebles, G; Sinha, S | 1 |
| Yee, J | 1 |
| Bregman, DB; Butcher, A; Goodnough, LT; Harrington, RA; Koch, TA; Morris, D; Onken, JE; Szczech, LA; Wolf, M | 1 |
| Gupta, A; Olp, J; Pai, A; Reddy, S; Zha, J; Zhuo, J | 1 |
| Brin, JF; Crommelin, DJ; Klinger, E; Mühlebach, S; Schellekens, H; Storm, G | 1 |
| Battegay, E; Breymann, C; Furrer, J; Krayenbuehl, PA; Schulthess, G | 1 |
| Dorrington, KL; León-Velarde, F; Nickol, AH; Privat, C; Rivera-Ch, M; Robbins, PA; Smith, TG; Talbot, NP | 1 |
| Bosch, MA; Bruguera, J; Cladellas, M; Comín-Colet, J; Farré, N; Gómez, M; Meroño, O; Molera, R; Segovia, A; Vila, J | 1 |
| Ávalos-Pinto, R; de la Llana-Ducrós, R; Garrido-Martín, P; Jimenez-Sosa, A; Martínez-Sanz, R; Nassar-Mansur, MI; Rodríguez Fortunez, PM; Virgos-Aller, TM | 1 |
| Chen, J; Chen, X; Cheng, M; Peng, Y; Yang, L; Yin, L | 1 |
| Bockeria, LA; Bockeria, O; Donakanian, S; Sokolskaya, M | 1 |
| Akarsu, S; Demir, H; Oguzoncul, F; Selek, S | 1 |
| Amorós-Amorós, F; Enríquez-Ascarza, R; González-Martinez, C; Millán-del Valle, I; Redondo-Pachón, MD; Sirvent-Pedreño, AE | 1 |
| Burden, R; Horgan, G; Moore, B; Pedlar, CR; Pollock, N; Whyte, GP | 1 |
| Barot, BS; Mehta, DM; Parejiya, PB; Shah, GB; Shelat, PK | 1 |
| Bentley, DP; Meek, EM | 1 |
| Akin, M; Atay, E; Erdogan, F; Karadeniz, C; Karakus, YT; Oztekin, O; Yilmaz, B | 1 |
| Cornelius, C; Goldenberg, H; Praschberger, M; Scheiber-Mojdehkar, B; Schitegg, M; Sturm, B | 1 |
| Boland, JP; Kusminsky, RE; Maxwell, D; Richmond, BK; Schlarb, CA; Todd Kuenstner, J; Willis Trammell, S; Witsberger, T | 1 |
| Hammami Ghorbel, H; Lacour, JP; Passeron, T | 1 |
| Mekic, M; Musanovic, A; Trnacevic, S | 1 |
| Chong, E; Kalia, V; Willsie, S; Winkle, P | 1 |
| Cava-Sumner, B; Domínguez-Ortega, J; Kindelan-Recarte, C; Montojo-Guillén, C; Nuñez-Acevedo, B; Rodríguez-Jiménez, B | 1 |
| Baranto, A; Barreto Henriksson, H; Brantsing, C; Junevik, K; Papadimitriou, N; Thorfve, A | 1 |
| Al-Makki, A; Bousher, A; Shepler, B; Sutton, J | 1 |
| Angerosa, M; Cao, G; Toblli, JE | 1 |
| Cozzolino, M; Funk, F; Phan, O; Rakov, V; Teitelbaum, I | 1 |
| Chong, EM; Covic, AC; Floege, J; Gaillard, S; Ketteler, M; Lisk, LJ; Mann, JF; Rastogi, A; Spinowitz, B; Sprague, SM | 1 |
| Greig, SL; Plosker, GL | 1 |
| Baron, F; Beguin, Y; Bonnet, C; De Prijck, B; Fillet, G; Hafraoui, K; Jaspers, A; Maertens, J; Schots, R; Servais, S; Willems, É | 1 |
| Burnier, M; Funk, F; Maillard, M; Malluche, HH; Phan, O; Stehle, JC | 1 |
| Lederer, SR; Schmid, H | 1 |
| Ademi, Z; Blank, PR; Braunhofer, PG; Gutzwiller, FS; Pfeil, AM; Schwenkglenks, M; Szucs, TD | 1 |
| Han, ZT; Hong, M; Li, H; Zhao, YS | 1 |
| Jang, SM; Pai, AB; Wegrzyn, N | 1 |
| Kobayashi, M; Maruyama, I; Maruyama, K; Tatemichi, S; Yaguchi, A; Yonekubo, S | 1 |
| Floege, J | 1 |
| Covic, AC; Floege, J; Ketteler, M; Lisk, L; Rakov, V; Rastogi, A; Sprague, SM | 1 |
| Botha, J; Chong, EM; Covic, AC; Floege, J; Ketteler, M; Rastogi, A; Sprague, SM | 1 |
| Akizawa, T; Fukagawa, M; Koiwa, F; Terao, A; Yokoyama, K | 1 |
| Covic, AC; Floege, J; Ketteler, M; Lisk, LJ; Mann, J; Rakov, V; Rastogi, A; Spinowitz, B; Sprague, SM | 1 |
| Akizawa, T; Fukagawa, M; Koiwa, F; Yokoyama, K | 1 |
| Bataille, P; Daroux, M; Delattre, V | 1 |
| Anderson, L; Coyne, DW; Ficociello, LH; Kossmann, RJ; Maddux, FW; Mullon, C; Ofsthun, NJ; Parameswaran, V; Sprague, SM; Vemula, S | 1 |
| Mitsuboshi, S; Nagai, K; Okajima, H; Yamada, H | 1 |
| Hayashi, H; Ichie, T; Sugiura, Y; Sugiyama, T; Suzuki, D | 1 |
| Neradova, A; Schumacher, SP; Schurgers, LJ; Vervloet, MG | 1 |
| Anderson, L; Coyne, DW; Ficociello, LH; Kalantar-Zadeh, K; Kossmann, RJ; Kwoh, C; Mullon, C; Ofsthun, NJ; Parameswaran, V | 1 |
| Fujii, H; Hamano, T; Isaka, Y; Teramukai, S; Tsujimoto, Y | 1 |
| Covic, AC; Floege, J; Ketteler, M; Rakov, V; Rastogi, A; Sprague, SM; Walpen, S | 1 |
| Covic, AC; Floege, J; Ketteler, M; Rakov, V; Rastogi, A; Spinowitz, B; Sprague, SM; Walpen, S | 1 |
| Kawashima, S; Minakuchi, J; Miya, K; Okada, K; Shima, H | 1 |
| Floege, J; Sprague, SM | 1 |
| Ando, T; Ito, K; Minegishi, A; Nagano, N; Ogawa, T; Tsutsui, T | 1 |
| Abe, M; Horikoshi, S; Maruyama, N; Moriuchi, M; Okamura, M; Otsuki, T; Shibahara, N; Suzuki, H; Utsunomiya, K | 1 |
| Alfieri, C; Cozzolino, M; Gallieni, M; Malberti, F; Mazzaferro, S; Messa, P; Russo, D | 1 |
| Chazot, C; Fadel, B; Jean, G; Kareche, M; Puyoo, O | 1 |
| Davis, S; Ficociello, LH; Kalantar-Zadeh, K; Kendrick, J; Kossmann, RJ; Mullon, C; Ofsthun, NJ; Parameswaran, V | 1 |
| Fujigaki, Y; Ishizawa, K; Kawachi, H; Kumagai, T; Kuro-O, M; Miura, Y; Morimoto, C; Nemoto, Y; Omizo, H; Sakai, K; Shibata, S; Shiraishi, T; Tamura, Y; Uchida, S; Yamazaki, O | 1 |
| Athienites, NV; Coyne, DW; Ficociello, LH; Kalantar-Zadeh, K; Kossmann, RJ; Mullon, C; Parameswaran, V | 1 |
| Akahane, K; Takeda, H; Tamai, Y; Tatemichi, S; Tsuchioka, K; Yaguchi, A; Yamamoto, S; Yonekubo, S | 1 |
| Faitatzidou, D; Lioulios, G; Minasidis, I; Papagianni, A; Sampani, E; Sarafidis, PA; Stangou, M; Tsouchnikas, I; Vainas, A | 1 |
| Hirai, K; Hoshino, T; Ito, K; Kitano, T; Minato, S; Miyazawa, H; Morishita, Y; Ookawara, S; Shindo, M; Ueda, Y | 1 |
| Covic, AC; Floege, J; Funk, F; Ketteler, M; Rastogi, A; Sprague, SM; Walpen, S | 1 |
| Iguchi, A; Ishioka, K; Kazama, JJ; Narita, I; Oda, A; Saeki, T; Suzutani, T; Tanaka, K; Yamamoto, S; Yamazaki, H | 1 |
| Covic, AC; Floege, J; Ketteler, M; Perrin, A; Rastogi, A; Sprague, SM; Walpen, S | 1 |
| Behets, GJ; Corremans, R; D'Haese, PC; Funk, F; Neven, E; Verhulst, A; Vervaet, BA; Walpen, S | 1 |
| Abitbol, CL; Ahn, SY; Balgradean, M; Enoiu, M; Fathallah-Shaykh, S; Fila, M; Greenbaum, LA; Jankauskiene, A; Jeck, N; Klaus, G; Nelson, R; Paredes, A; Perrin, A; Stoica, C; Swinford, RD; Wickman, L | 1 |
| Arens, HJ; Chazot, C; Di Benedetto, A; Ferreira, A; Feuersenger, A; Gurevich, K; Ramos, R; Stuard, S; Walpen, S; Wolf, M | 1 |
| Fujii, H; Hamano, T; Isaka, Y; Koiwa, F; Sakaguchi, Y; Tanaka, R; Tatsugami, F; Teramukai, S; Tomiyama, N; Tsujimoto, Y | 1 |
| Li, W; Liao, X; Ou, J; Rao, J; Xue, C; Zhu, Y | 1 |
| Fujino, T; Kaburagi, N; Morimoto, K; Oya, M; Takemitsu, TY; Yamashita, N; Yoshida, T | 1 |
| Ketteler, M; Sprague, SM | 1 |
| Araujo, R; Bancu, I; Bonal, J; Graterol, F; Merino-Ribas, A; Noguera-Julian, M; Paredes, R; Sampaio-Maia, B; Vergara, A | 1 |
| Coyne, DW; Kalantar-Zadeh, K; Ramos, R; Sprague, SM; Vervloet, M | 1 |
| Abdelbary, MMH; Conrads, G; Floege, J; Krüger, T; Kuppe, C; Michael, SS | 1 |
| Andrews, ES; Kendrick, J; Perez, L; Ramirez-Renteria, L; Reddin, R; Teitelbaum, I; Wilson, G; You, Z | 1 |
| Brent, J; Furmaga, J; Meadows, J; Weiss, ST | 1 |
13 review(s) available for sucrose and ferric oxide, saccharated
| Article | Year |
|---|---|
[Indications and practical management of parenteral iron therapy].
Topics: Administration, Oral; Adult; Anemia, Iron-Deficiency; Child; Erythrocyte Count; Erythropoiesis; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Glucaric Acid; Humans; Infusions, Intravenous; Injections, Intravenous; Iron Deficiencies; Male; Renal Dialysis; Sucrose; Time Factors; Transferrin | 2003 |
[Blood conservation approaches in orthopedic surgery].
Topics: Anemia; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Blood Transfusion, Autologous; Drug Administration Schedule; Erythropoietin; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Glucaric Acid; Hematinics; Hemodilution; Humans; Intraoperative Complications; Orthopedic Procedures; Postoperative Hemorrhage; Preoperative Care; Recombinant Proteins; Sucrose; Time Factors; Tranexamic Acid; Transfusion Reaction | 2008 |
A review of sucroferric oxyhydroxide for the treatment of hyperphosphatemia in patients receiving dialysis.
Topics: Chelating Agents; Drug Combinations; Ferric Compounds; Humans; Hyperphosphatemia; Renal Dialysis; Renal Insufficiency, Chronic; Sucrose; United States | 2014 |
Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric Oxyhydroxide.
Topics: Animals; Chelating Agents; Disease Models, Animal; Dogs; Drug Combinations; Ferric Compounds; Gastrointestinal Absorption; Humans; Hyperphosphatemia; Kidney; Phosphates; Rats; Renal Insufficiency, Chronic; Risk Assessment; Sucrose; Uremia; Vascular Calcification | 2014 |
Sucroferric oxyhydroxide: a review in hyperphosphataemia in chronic kidney disease patients undergoing dialysis.
Topics: Chelating Agents; Drug Combinations; Drug Interactions; Ferric Compounds; Humans; Hyperphosphatemia; Phosphates; Practice Guidelines as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Sucrose | 2015 |
Novel iron-containing phosphate binders for treatment of hyperphosphatemia.
Topics: Animals; Carbonates; Clinical Trials as Topic; Drug Combinations; Ferric Compounds; Humans; Hyperphosphatemia; Iron; Lanthanum; Magnesium; Phosphates; Renal Insufficiency, Chronic; Sevelamer; Starch; Sucrose | 2015 |
Iron-based phosphate binders--a new element in management of hyperphosphatemia.
Topics: Animals; Drug Combinations; Ferric Compounds; Humans; Hyperphosphatemia; Medication Adherence; Phosphates; Renal Insufficiency, Chronic; Sevelamer; Sucrose | 2016 |
Phosphate binders in chronic kidney disease: a systematic review of recent data.
Topics: Drug Combinations; Ferric Compounds; Humans; Hyperphosphatemia; Lanthanum; Phosphates; Polyamines; Renal Insufficiency, Chronic; Sevelamer; Sucrose | 2016 |
Sucroferric oxyhydroxide for the treatment of hyperphosphatemia.
Topics: Chelating Agents; Clinical Trials as Topic; Drug Combinations; Ferric Compounds; Government Regulation; Humans; Hyperphosphatemia; Phosphates; Renal Dialysis; Renal Insufficiency, Chronic; Sucrose; Treatment Outcome | 2018 |
[Hyperphosphatemia in dialysis: which binder?]
Topics: Chelating Agents; Chelation Therapy; Cohort Studies; Drug Combinations; Ferric Compounds; Gastrointestinal Diseases; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Kidney Failure, Chronic; Multicenter Studies as Topic; Patient Compliance; Phosphates; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Renal Dialysis; Sucrose | 2018 |
Using iron-based phosphate binders in phosphate reduction and anemia improvement in patients receiving dialysis: a meta-analysis of randomized controlled trials.
Topics: Anemia; Carbonates; Drug Combinations; Ferric Compounds; Humans; Hyperphosphatemia; Iron; Magnesium; Randomized Controlled Trials as Topic; Renal Dialysis; Starch; Sucrose; Treatment Outcome | 2021 |
A safety evaluation of sucroferric oxyhydroxide for the treatment of hyperphosphatemia.
Topics: Chelating Agents; Drug Combinations; Drug Interactions; Ferric Compounds; Humans; Hyperphosphatemia; Renal Dialysis; Renal Insufficiency, Chronic; Sucrose | 2021 |
Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence.
Topics: Drug Combinations; Ferric Compounds; Humans; Hyperphosphatemia; Iron; Phosphates; Phosphorus; Prospective Studies; Randomized Controlled Trials as Topic; Renal Dialysis; Retrospective Studies; Sucrose | 2022 |
36 trial(s) available for sucrose and ferric oxide, saccharated
| Article | Year |
|---|---|
Pharmacokinetics of iron(III)-hydroxide sucrose complex after a single intravenous dose in healthy volunteers.
Topics: Adult; Erythropoiesis; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Half-Life; Humans; Injections, Intravenous; Iron; Male; Middle Aged; Receptors, Transferrin; Spectrophotometry, Atomic; Sucrose; Transferrin | 1996 |
Intravenous iron sucrose complex in the treatment of iron deficiency anemia during pregnancy.
Topics: Administration, Oral; Adult; Anemia, Iron-Deficiency; Erythrocyte Indices; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Ferrous Compounds; Glucaric Acid; Hematinics; Hemoglobins; Humans; Injections, Intravenous; Pregnancy; Pregnancy Complications, Hematologic; Prospective Studies; Reference Values; Sucrose; Time Factors | 1996 |
The efficiency of fractionated parenteral iron treatment in CAPD patients.
Topics: Adult; Anemia; Drug Administration Schedule; Drug Therapy, Combination; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Glucaric Acid; Hematocrit; Humans; Injections, Intravenous; Kidney Failure, Chronic; Male; Middle Aged; Organization and Administration; Peritoneal Dialysis, Continuous Ambulatory; Recombinant Proteins; Sucrose; Transferrin | 1997 |
Iron supplementation in haemodialysis--practical clinical guidelines.
Topics: Anemia, Iron-Deficiency; Biomarkers; Drug Administration Routes; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Follow-Up Studies; Glucaric Acid; Hemoglobins; Humans; Iron; Iron Deficiencies; Kidney Failure, Chronic; Male; Middle Aged; Nutritional Support; Practice Guidelines as Topic; Prospective Studies; Recombinant Proteins; Renal Dialysis; Sucrose; Transferrin | 1998 |
The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Drug Therapy, Combination; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Glucaric Acid; Hematocrit; Humans; Infusions, Intravenous; Injections, Subcutaneous; Kidney Failure, Chronic; Male; Middle Aged; Recombinant Proteins; Renal Dialysis; Sucrose | 2001 |
A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEpo.
Topics: Drug Administration Schedule; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Glucaric Acid; Hemoglobins; Humans; Leukocyte Count; Male; Middle Aged; Platelet Count; Recombinant Proteins; Renal Dialysis; Sucrose; Time Factors; Transferrin | 2001 |
The effects of intravenous iron treatment on oxidant stress and erythrocyte deformability in hemodialysis patients.
Topics: Adult; Dose-Response Relationship, Drug; Erythrocyte Deformability; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Infusions, Intravenous; Injections, Intravenous; Iron; Kidney Failure, Chronic; Male; Middle Aged; Oxidative Stress; Renal Dialysis; Sucrose; Time Factors | 2003 |
[Post-haemodilution anaemia in paediatric cardiac surgery: benefit of intravenous iron therapy].
Topics: Anemia; Cardiac Surgical Procedures; Child; Child, Preschool; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Glucaric Acid; Hemodilution; Hemoglobins; Humans; Infant; Infusions, Intravenous; Male; Postoperative Complications; Reticulocyte Count; Sucrose | 2005 |
[Postpartum and early postoperative anemia after gynecological surgery: treatment with intravenous iron].
Topics: Adolescent; Adult; Anemia; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Gynecologic Surgical Procedures; Humans; Injections, Intravenous; Prospective Studies; Puerperal Disorders; Sucrose | 2006 |
[Intravenous treatment of postpartum anemia with trivalent ferrum preparation].
Topics: Anemia, Iron-Deficiency; Blood Cell Count; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Glucaric Acid; Humans; Infusions, Intravenous; Pregnancy; Puerperal Disorders; Sucrose | 2007 |
Effect of intravenous iron supplementation on hepatic cytochrome P450 3A4 activity in hemodialysis patients: a prospective, open-label study.
Topics: Breath Tests; Cytochrome P-450 Enzyme System; Erythromycin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Humans; Infusions, Intravenous; Iron Deficiencies; Liver; Male; Middle Aged; Prospective Studies; Renal Dialysis; Sucrose | 2007 |
A 12-week randomised study comparing intravenous iron sucrose versus oral ferrous sulphate for treatment of postpartum anemia.
Topics: Administration, Oral; Adolescent; Adult; Anemia; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Ferrous Compounds; Glucaric Acid; Hemoglobins; Humans; Infusions, Intravenous; Middle Aged; Postpartum Period; Prospective Studies; Quality of Life; Sucrose | 2008 |
Intravenous iron in chronic kidney disease: haemoglobin change shortly after treatment of patients neither on dialysis nor on erythropoietin.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Cost-Benefit Analysis; Drug Administration Schedule; Drug Monitoring; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Glomerular Filtration Rate; Glucaric Acid; Hemoglobins; Humans; Infusions, Intravenous; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis; Severity of Illness Index; Sucrose; Transferrin; Treatment Outcome | 2008 |
Randomized evaluation of efficacy and safety of ferric carboxymaltose in patients with iron deficiency anaemia and impaired renal function (REPAIR-IDA): rationale and study design.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Iron-Deficiency; Biomarkers; Cardiovascular Diseases; Chronic Disease; Female; Ferric Compounds; Ferric Oxide, Saccharated; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Glucaric Acid; Hemoglobins; Humans; Kidney Diseases; Male; Maltose; Middle Aged; Risk Factors; Sucrose; Treatment Outcome | 2010 |
Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration.
Topics: Adult; Double-Blind Method; Fatigue; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Glucaric Acid; Humans; Infusions, Intravenous; Iron; Iron Deficiencies; Patient Selection; Placebos; Premenopause; Research Design; Sucrose | 2011 |
Intravenous iron supplementation may protect against acute mountain sickness: a randomized, double-blinded, placebo-controlled trial.
Topics: Acute Disease; Adult; Altitude Sickness; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Glucaric Acid; Hematocrit; Humans; Injections, Intravenous; Male; Oxygen; Severity of Illness Index; Sucrose; Young Adult | 2011 |
The effect of intravenous and oral iron administration on perioperative anaemia and transfusion requirements in patients undergoing elective cardiac surgery: a randomized clinical trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anemia, Iron-Deficiency; Blood Transfusion; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Chi-Square Distribution; Double-Blind Method; Elective Surgical Procedures; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferrous Compounds; Glucaric Acid; Hematinics; Humans; Infusions, Intravenous; Male; Middle Aged; Spain; Sucrose; Tablets; Time Factors; Treatment Failure | 2012 |
[Multi-frequency low-dose intravenous iron on oxidative stress in maintenance hemodialysis patients].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Injections, Intravenous; Kidney Failure, Chronic; Male; Middle Aged; Oxidative Stress; Renal Dialysis; Sucrose; Young Adult | 2012 |
Iron deficiency anemia and levels of oxidative stress induced by treatment modality.
Topics: Administration, Oral; Adolescent; Anemia, Iron-Deficiency; Antioxidants; Child; Child, Preschool; Developing Countries; Dose-Response Relationship, Drug; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferrous Compounds; Glucaric Acid; Glycine; Hemoglobinometry; Humans; Infant; Infusions, Intravenous; Injections, Intramuscular; Male; Oxidative Stress; Sucrose; Turkey | 2013 |
Responsiveness to parenteral iron therapy in children with oral iron-refractory iron-deficiency anemia.
Topics: Administration, Oral; Adolescent; Anemia, Iron-Deficiency; Child; Child, Preschool; Drug Resistance; Erythrocyte Indices; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferrous Compounds; Glucaric Acid; Humans; Infusions, Intravenous; Iron; Male; Sucrose; Treatment Outcome | 2014 |
Drug-drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjects.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Anticoagulants; Area Under Curve; Cardiotonic Agents; Chelating Agents; Digoxin; Diuretics; Drug Administration Schedule; Drug Combinations; Drug Interactions; Female; Ferric Compounds; Furosemide; Half-Life; Healthy Volunteers; Humans; Losartan; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Models, Statistical; Omeprazole; Proton Pump Inhibitors; Risk Assessment; Sucrose; Warfarin; Young Adult | 2014 |
Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients.
Topics: Drug Combinations; Female; Ferric Compounds; Humans; Hyperphosphatemia; Iron; Male; Middle Aged; Phosphorus; Prognosis; Renal Dialysis; Sucrose; Time Factors | 2015 |
Long-term safety follow-up of a randomized trial of darbepoetin alpha and intravenous iron following autologous hematopoietic cell transplantation.
Topics: Anemia; Darbepoetin alfa; Drug Therapy, Combination; Erythropoietin; Ferric Compounds; Ferric Oxide, Saccharated; Follow-Up Studies; Glucaric Acid; Hematinics; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Injections, Intravenous; Sucrose; Survival Analysis; Transplantation, Autologous | 2015 |
Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide.
Topics: Drug Combinations; Female; Ferric Compounds; Humans; Hyperphosphatemia; Iron; Male; Middle Aged; Prognosis; Renal Dialysis; Sucrose | 2017 |
Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Biomarkers, Pharmacological; Bone Density Conservation Agents; Chelating Agents; Drug Combinations; Drug Interactions; Ergocalciferols; Female; Ferric Compounds; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Male; Middle Aged; Parathyroid Hormone; Receptors, Calcitriol; Renal Dialysis; Renal Insufficiency, Chronic; Sevelamer; Sucrose | 2016 |
Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: A randomized, open-label, multicentre, 12-week phase III study.
Topics: Administration, Oral; Aged; Biomarkers; Calcium; Chelating Agents; Drug Administration Schedule; Drug Combinations; Female; Ferric Compounds; Humans; Hyperphosphatemia; Japan; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis; Renal Insufficiency, Chronic; Sevelamer; Sucrose; Tablets; Time Factors; Treatment Outcome | 2017 |
One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis.
Topics: Adult; Aged; Combined Modality Therapy; Drug Combinations; Female; Ferric Compounds; Humans; Hyperphosphatemia; Male; Medication Adherence; Middle Aged; Peritoneal Dialysis; Phosphates; Sucrose; Treatment Outcome | 2017 |
Long-Term Assessment of the Safety and Efficacy of PA21 (Sucroferric Oxyhydroxide) in Japanese Hemodialysis Patients With Hyperphosphatemia: An Open-Label, Multicenter, Phase III Study.
Topics: Aged; Asian People; Drug Combinations; Female; Ferric Compounds; Humans; Hyperphosphatemia; Japan; Kidney Failure, Chronic; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis; Sucrose; Treatment Outcome | 2017 |
Rationale, design, and characteristics of a trial to evaluate the new phosphate iron-based binder sucroferric oxyhydroxide in dialysis patients with the goal of advancing the practice of E.B.M. (EPISODE).
Topics: Calcinosis; Chelating Agents; Coronary Artery Disease; Drug Combinations; Ferric Compounds; Humans; Hyperphosphatemia; Iron; Phosphates; Randomized Controlled Trials as Topic; Renal Dialysis; Sucrose | 2018 |
Long-term efficacy and safety of sucroferric oxyhydroxide in African American dialysis patients.
Topics: Black or African American; Drug Combinations; Female; Ferric Compounds; Humans; Male; Middle Aged; Renal Dialysis; Sucrose | 2018 |
Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients.
Topics: Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Drug Combinations; Female; Ferric Compounds; Fibroblast Growth Factor-23; Follow-Up Studies; Humans; Hyperphosphatemia; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis; Sevelamer; Sucrose; Time Factors; Treatment Outcome | 2019 |
Effect of Sucroferric Oxyhydroxide on Fibroblast Growth Factor 23 Levels in Hemodialysis Patients.
Topics: Aged; Drug Combinations; Female; Ferric Compounds; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Hematinics; Humans; Iron; Male; Middle Aged; Phosphates; Prospective Studies; Renal Dialysis; Sucrose | 2018 |
Characteristics of Patients Who Achieve Serum Phosphorus Control on Sucroferric Oxyhydroxide or Sevelamer Carbonate: A post hoc Analysis of a Phase 3 Study.
Topics: Adult; Age Factors; Aged; Calcimimetic Agents; Chelating Agents; Drug Combinations; Female; Ferric Compounds; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperphosphatemia; Logistic Models; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis; Renal Insufficiency, Chronic; Sevelamer; Sucrose; Vitamin D | 2020 |
Safety and efficacy of sucroferric oxyhydroxide in pediatric patients with chronic kidney disease.
Topics: Adolescent; Child; Drug Combinations; Ferric Compounds; Humans; Hyperphosphatemia; Phosphorus; Renal Dialysis; Renal Insufficiency, Chronic; Sucrose | 2021 |
Optimal Phosphate Control Related to Coronary Artery Calcification in Dialysis Patients.
Topics: Adult; Aged; Calcinosis; Coronary Artery Disease; Disease Progression; Drug Combinations; Female; Ferric Compounds; Humans; Hyperphosphatemia; Lanthanum; Male; Middle Aged; Phosphates; Renal Dialysis; Sequestering Agents; Sucrose; Young Adult | 2021 |
Gut microbiome in hemodialysis patients treated with calcium acetate or treated with sucroferric oxyhydroxide: a pilot study.
Topics: Acetates; Calcium Compounds; Drug Combinations; Ferric Compounds; Gastrointestinal Microbiome; Humans; Hyperphosphatemia; Pilot Projects; Renal Dialysis; RNA, Ribosomal, 16S; Sucrose | 2022 |
72 other study(ies) available for sucrose and ferric oxide, saccharated
| Article | Year |
|---|---|
[Intravenous iron in the treatment of postoperative anemia in surgery of the spine in infants and adolescents].
Topics: Administration, Oral; Adolescent; Adult; Anemia; Blood Loss, Surgical; Child; Child, Preschool; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Injections, Intravenous; Iron; Postoperative Complications; Spinal Fusion; Sucrose | 1998 |
Kinetic analysis of 52Fe-labelled iron(III) hydroxide-sucrose complex following bolus administration using positron emission tomography.
Topics: Bone Marrow; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Liver; Sucrose; Tomography, Emission-Computed | 1999 |
Pharmacokinetics and red cell utilization of iron(III) hydroxide-sucrose complex in anaemic patients: a study using positron emission tomography.
Topics: Adult; Anemia; Erythrocytes; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Glucaric Acid; Humans; Male; Middle Aged; Sucrose; Tomography, Emission-Computed; Transferrin | 1999 |
Intravenous iron (III) hydroxide-sucrose complex for anaemia in epidermolysis bullosa.
Topics: Anemia, Iron-Deficiency; Child; Epidermolysis Bullosa Dystrophica; Erythropoietin; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Male; Recombinant Proteins; Sucrose | 1999 |
Oral phosphate binders: phosphate binding capacity of iron (III) hydroxide complexes containing saccharides and their effect on the urinary excretion of calcium and phosphate in rats.
Topics: Administration, Oral; Adsorption; Animals; Calcium; Feces; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hydrogen-Ion Concentration; In Vitro Techniques; Male; Phosphates; Random Allocation; Rats; Rats, Wistar; Structure-Activity Relationship; Sucrose; Time Factors | 1999 |
Iron sucrose or ferric gluconate?
Topics: Anemia, Iron-Deficiency; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Injections, Intravenous; Renal Dialysis; Sucrose; Terminology as Topic | 2001 |
Aggressive therapy of congestive heart failure and associated chronic renal failure with medications and correction of anemia stops or slows the progression of both diseases.
Topics: Aged; Anemia; Disease Progression; Drug Therapy, Combination; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glomerular Filtration Rate; Glucaric Acid; Heart Failure; Humans; Kidney Failure, Chronic; Male; Recombinant Proteins; Stroke Volume; Sucrose | 2001 |
Risk of bacterial infection in patients under intravenous iron therapy: dose versus length of treatment.
Topics: Adult; Bacterial Infections; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Male; Middle Aged; Renal Dialysis; Sucrose | 2001 |
Induction of protein oxidation by intravenous iron in hemodialysis patients: role of inflammation.
Topics: Aged; Aged, 80 and over; Blood Proteins; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Glycation End Products, Advanced; Humans; Inflammation; Infusions, Intravenous; Male; Middle Aged; Oxidation-Reduction; Oxidative Stress; Renal Dialysis; Sodium Chloride; Sucrose | 2002 |
[Changes in iron metabolism and erythropoietin requirements after the switch from ferric gluconate to iron saccharose. Is it worth the increased expense?].
Topics: Aged; Aged, 80 and over; Anemia; Cost-Benefit Analysis; Drug Costs; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Iron; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis; Spain; Sucrose | 2003 |
Vibrio vulnificus infection in a hemodialysis patient receiving intravenous iron therapy.
Topics: Aged; Animals; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Infusions, Intravenous; Male; Ostreidae; Renal Dialysis; Sucrose; Vibrio Infections; Vibrio vulnificus | 2003 |
[Injectable iron-oxide-sucrose].
Topics: Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Iron; Oxides; Sucrose | 1956 |
[Use of venofer for iron deficiency correction in patients undergoing programmed hemodialysis].
Topics: Administration, Oral; Adolescent; Adult; Aged; Anemia, Iron-Deficiency; Drug Costs; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hemoglobins; Humans; Injections, Intravenous; Kidney Diseases; Male; Middle Aged; Renal Dialysis; Sucrose; Treatment Outcome | 2003 |
[Antiphospholipid antibodies as a cause of adverse pregnancy outcome. Therapeutic approach].
Topics: Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Heparin; Humans; Infant, Newborn; Male; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Sucrose | 2003 |
Labile iron in parenteral iron formulations: a quantitative and comparative study.
Topics: Biological Assay; Chemistry, Pharmaceutical; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Iron; Iron-Dextran Complex; Protein Binding; Sucrose; Transferrin | 2004 |
The use of androgens in anaemia resistant to erythropoietin and i.v. iron in patients with heart and renal failure.
Topics: Aged; Anemia; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Heart Failure; Humans; Injections, Intravenous; Kidney Failure, Chronic; Male; Nandrolone; Nandrolone Decanoate; Sucrose | 2004 |
Treatment of anaemia in inflammatory bowel disease with iron sucrose.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Colitis, Ulcerative; Crohn Disease; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Humans; Infusions, Intravenous; Male; Middle Aged; Retreatment; Retrospective Studies; Sucrose; Treatment Outcome | 2004 |
[Safety and usefulness of parenteral iron in the management of anemia due to hip fracture in the elderly].
Topics: Aged; Aged, 80 and over; Anemia; Blood Loss, Surgical; Blood Transfusion; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Hip Fractures; Humans; Infusions, Intravenous; Iron; Male; Sucrose | 2004 |
[How to avoid a haemotransfusion which is not lifesaving? (our experience with administration of intravenous iron to pregnant women and young mothers)].
Topics: Anemia, Iron-Deficiency; Blood Transfusion; Drug Administration Schedule; Erythrocyte Count; Female; Ferric Compounds; Ferric Oxide, Saccharated; Gestational Age; Glucaric Acid; Hemoglobins; Humans; Injections, Intravenous; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Prospective Studies; Sucrose | 2004 |
Intravenous iron in a primary-care clinic.
Topics: Anemia, Iron-Deficiency; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Glucaric Acid; Humans; Injections, Intravenous; Renal Insufficiency; Sucrose | 2005 |
Hypersensitivity reactions and deaths associated with intravenous iron preparations.
Topics: Adverse Drug Reaction Reporting Systems; Algorithms; Anaphylaxis; Drug Hypersensitivity; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Infusions, Intravenous; Iron-Dextran Complex; Retrospective Studies; Severity of Illness Index; Sucrose; United States | 2005 |
Update on adverse drug events associated with parenteral iron.
Topics: Adverse Drug Reaction Reporting Systems; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Humans; Iron-Dextran Complex; Sucrose | 2006 |
Re: blood transfusion and orthognathic surgery a thing of the past?
Topics: Blood Transfusion; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hemoglobins; Humans; Infusions, Intravenous; Oral Surgical Procedures; Sucrose | 2006 |
[Use of Venofer in management of anemia in cancer patients].
Topics: Adult; Aged; Anemia; Disease Progression; Drug Administration Schedule; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hemoglobins; Humans; Male; Middle Aged; Neoplasms; Quality of Life; Sucrose; Time Factors; Treatment Outcome | 2006 |
[Ferropenic anemia: some comments].
Topics: Anemia, Iron-Deficiency; Celiac Disease; Diagnosis, Differential; Ferric Compounds; Ferric Oxide, Saccharated; Folic Acid Deficiency; Glucaric Acid; Humans; Injections, Intravenous; Iron; Sucrose | 2006 |
[Current recommendations for the treatment of iron deficiency anemia].
Topics: Anemia, Iron-Deficiency; Biomarkers; Drug Therapy, Combination; Epoetin Alfa; Erythrocyte Count; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Glucaric Acid; Hematinics; Hematocrit; Hemoglobins; Humans; Injections, Intravenous; Pregnancy; Pregnancy Complications, Hematologic; Recombinant Proteins; Sucrose; Switzerland; Transferrin | 2007 |
Effect of intravenous iron sucrose on oxidative stress in peritoneal dialysis patients.
Topics: Adult; Aged; C-Reactive Protein; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Glutathione Peroxidase; Humans; Injections, Intravenous; Male; Malondialdehyde; Middle Aged; Oxidative Stress; Peritoneal Dialysis, Continuous Ambulatory; Sucrose | 2007 |
Intravenous treatment of anaemia with an iron-sucrose preparation.
Topics: Anemia; Anemia, Sickle Cell; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Iron; Sucrose | 1949 |
Comparison of intravenous iron sucrose versus low-molecular-weight iron dextran in chronic kidney disease.
Topics: Anemia, Iron-Deficiency; Drug-Related Side Effects and Adverse Reactions; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hematinics; Humans; Infusions, Intravenous; Iron-Dextran Complex; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Sucrose | 2009 |
Iron replacement therapy: assessing today's options to prepare for bundling.
Topics: Anemia, Iron-Deficiency; Chemistry, Pharmaceutical; Dextrans; Drug Costs; Ferric Compounds; Ferric Oxide, Saccharated; Ferrosoferric Oxide; Glucaric Acid; Hematinics; Humans; Infusions, Intravenous; Iron Compounds; Iron-Dextran Complex; Medicare; Reimbursement Mechanisms; Renal Dialysis; Risk Adjustment; Safety; Sucrose; Treatment Outcome; United States | 2010 |
Effect of different intravenous iron preparations on lymphocyte intracellular reactive oxygen species generation and subpopulation survival.
Topics: CD4-Positive T-Lymphocytes; Cell Survival; Cells, Cultured; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; GPI-Linked Proteins; Humans; Iron-Dextran Complex; Lymphocyte Subsets; Molecular Weight; Oxidative Stress; Reactive Oxygen Species; Receptors, IgG; Sucrose | 2010 |
The therapeutic equivalence of complex drugs.
Topics: Anticoagulants; Biological Products; Congresses as Topic; Consumer Product Safety; Drugs, Generic; Evidence-Based Medicine; Ferric Compounds; Ferric Oxide, Saccharated; Glatiramer Acetate; Glucaric Acid; Hematinics; Heparin, Low-Molecular-Weight; Humans; Immunosuppressive Agents; Legislation, Drug; Liposomes; Patents as Topic; Peptides; Proteins; Risk Assessment; Sucrose; Therapeutic Equivalency | 2011 |
Effects of preoperative intravenous erythropoietin plus iron on outcome in anemic patients after cardiac valve replacement.
Topics: Aged; Anemia; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erythrocyte Transfusion; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Follow-Up Studies; Glucaric Acid; Heart Valve Diseases; Heart Valve Prosthesis Implantation; Hematinics; Hospital Mortality; Humans; Infusions, Intravenous; Male; Postoperative Period; Preoperative Care; Prospective Studies; Recombinant Proteins; Risk Factors; Spain; Sucrose; Survival Rate; Treatment Outcome | 2012 |
eComment. The problem of anaemia correction in cardiac surgery patients.
Topics: Anemia, Iron-Deficiency; Blood Transfusion; Cardiac Surgical Procedures; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferrous Compounds; Glucaric Acid; Hematinics; Humans; Male; Sucrose | 2012 |
Adverse reaction to intravenous iron: hypersensitivity or secondary side effect?
Topics: Adult; Drug Hypersensitivity; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Infusions, Intravenous; Sucrose | 2013 |
A case study of an iron-deficient female Olympic 1500-m runner.
Topics: Adolescent; Anemia, Iron-Deficiency; Athletes; Athletic Performance; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Glucaric Acid; Hematinics; Hemoglobins; Humans; Injections, Intravenous; Lactic Acid; Oxygen Consumption; Running; Sucrose; Young Adult | 2013 |
Physicochemical and structural characterization of iron-sucrose formulations: a comparative study.
Topics: Anemia, Iron-Deficiency; Chromatography, Gel; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Magnetic Resonance Spectroscopy; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Spectroscopy, Fourier Transform Infrared; Sucrose | 2014 |
Clinical and biochemical improvement following low-dose intravenous iron therapy in a patient with erythropoietic protoporphyria.
Topics: Administration, Intravenous; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Male; Protoporphyria, Erythropoietic; Sucrose; Treatment Outcome; Young Adult | 2013 |
Bioavailability and stability of intravenous iron sucrose originator versus generic iron sucrose AZAD.
Topics: Anemia, Iron-Deficiency; Biological Availability; Cell Culture Techniques; Dose-Response Relationship, Drug; Drug Liberation; Drug Stability; Drugs, Generic; Enzyme-Linked Immunosorbent Assay; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Glucaric Acid; Hep G2 Cells; Humans; Injections, Intravenous; Macrophages; Spectrophotometry, Atomic; Sucrose | 2015 |
Identification of the sentinel node by ultrasonography in patients with breast cancer.
Topics: Adult; Axilla; Biopsy, Fine-Needle; Breast Neoplasms; Breast Neoplasms, Male; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Image-Guided Biopsy; Lymph Nodes; Male; Radiopharmaceuticals; Sentinel Lymph Node Biopsy; Signal Processing, Computer-Assisted; Sucrose; Technetium; Ultrasonography; Young Adult | 2014 |
Successful treatment with 532-nm Q-switched Nd:YAG laser of cutaneous siderosis following intravenous iron extravasation.
Topics: Aged; Anemia, Iron-Deficiency; Extravasation of Diagnostic and Therapeutic Materials; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Humans; Lasers, Solid-State; Male; Skin Diseases; Sucrose | 2015 |
The influence of inflammatory markers and CRP predictive value in relation to the target hemoglobin level in patients on chronic hemodialysis.
Topics: Aged; Anemia; Biomarkers; C-Reactive Protein; Case-Control Studies; Cross-Sectional Studies; Erythropoietin; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferritins; Fibrinogen; Glucaric Acid; Hemoglobins; Humans; Inflammation; Kidney Failure, Chronic; Male; Middle Aged; Predictive Value of Tests; Renal Dialysis; ROC Curve; Sucrose | 2013 |
Rapid iron desensitization after generalized urticaria and facial angioedema.
Topics: Anemia, Iron-Deficiency; Angioedema; Desensitization, Immunologic; Drug Hypersensitivity; Female; Ferric Compounds; Ferric Oxide, Saccharated; Ferrous Compounds; Glucaric Acid; Humans; Middle Aged; Sucrose; Urticaria | 2014 |
Cell viability and chondrogenic differentiation capability of human mesenchymal stem cells after iron labeling with iron sucrose.
Topics: Adolescent; Adult; Aggrecans; Biomarkers; Cell Differentiation; Cell Survival; Cells, Cultured; Chondrocytes; Chondrogenesis; Collagen Type II; Ferric Compounds; Ferric Oxide, Saccharated; Flow Cytometry; Gene Expression; Glucaric Acid; Humans; Immunohistochemistry; Immunophenotyping; Iron; Mesenchymal Stem Cells; Middle Aged; Reverse Transcriptase Polymerase Chain Reaction; SOX9 Transcription Factor; Staining and Labeling; Sucrose; Time Factors; Transforming Growth Factor beta; Young Adult | 2014 |
Nitrosative stress and apoptosis in non-anemic healthy rats induced by intravenous iron sucrose similars versus iron sucrose originator.
Topics: Animals; Apoptosis; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Injections, Intradermal; Interleukin-6; Liver; Male; Rats, Sprague-Dawley; Reactive Nitrogen Species; Stress, Physiological; Sucrose; Tumor Necrosis Factor-alpha | 2015 |
Effects of Sucroferric Oxyhydroxide Compared to Lanthanum Carbonate and Sevelamer Carbonate on Phosphate Homeostasis and Vascular Calcifications in a Rat Model of Chronic Kidney Failure.
Topics: Animals; Body Weight; Disease Models, Animal; Drug Combinations; Ferric Compounds; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Homeostasis; Kidney Failure, Chronic; Lanthanum; Male; Mortality; Phosphates; Rats, Wistar; Sevelamer; Sucrose; Vascular Calcification | 2015 |
Cost Effectiveness of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in the Treatment of Hyperphosphataemia in Patients Receiving Dialysis, from the Perspective of the National Health Service in Scotland.
Topics: Cost-Benefit Analysis; Drug Combinations; Ferric Compounds; Humans; Hyperphosphatemia; Markov Chains; Models, Economic; National Health Programs; Quality-Adjusted Life Years; Renal Dialysis; Scotland; Sevelamer; Sucrose | 2015 |
Transport of sucrose-modified nanoscale zero-valent iron in saturated porous media: role of media size, injection rate and input concentration.
Topics: Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Groundwater; Iron; Kinetics; Metal Nanoparticles; Porosity; Silicon Dioxide; Sucrose; Suspensions | 2015 |
Comparison of Phosphate Binding Capacities of PA21, A Novel Phosphate Binder, with those of other Phosphate Binders in vitro and in vivo.
Topics: Administration, Oral; Animals; Calcium Carbonate; Chelating Agents; Drug Combinations; Ferric Compounds; Hyperphosphatemia; Lanthanum; Male; Phosphates; Rats; Rats, Sprague-Dawley; Sevelamer; Sucrose | 2016 |
[Sucroferric oxyhydroxide, a novel iron-based phosphate binder. Which current use in dialysis patients?]
Topics: Chelating Agents; Drug Combinations; Evidence-Based Medicine; Ferric Compounds; Guidelines as Topic; Humans; Hyperphosphatemia; Randomized Controlled Trials as Topic; Renal Dialysis; Sevelamer; Sucrose; Treatment Outcome | 2017 |
Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: A retrospective analysis of pharmacy data
.
Topics: Adult; Aged; Drug Combinations; Female; Ferric Compounds; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Male; Middle Aged; Phosphorus; Renal Dialysis; Retrospective Studies; Sucrose | 2017 |
[Low Continuity Rate of Sucroferric Oxyhydroxide among Japanese Hemodialysis Patients with High Phosphate Binder Pill Burden].
Topics: Aged; Asian People; Chelating Agents; Drug Administration Schedule; Drug Combinations; Drug Substitution; Ferric Compounds; Humans; Male; Middle Aged; Phosphates; Polyamines; Prospective Studies; Renal Dialysis; Sevelamer; Sucrose; Tablets; Time Factors | 2018 |
Efficacy of sucroferric oxyhydroxide treatment in Japanese hemodialysis patients and its effect on gastrointestinal symptoms.
Topics: Aged; Chelating Agents; Constipation; Diarrhea; Drug Combinations; Drug Therapy, Combination; Female; Ferric Compounds; Humans; Hyperphosphatemia; Japan; Male; Middle Aged; Phosphorus; Renal Dialysis; Sucrose; Time Factors | 2017 |
Influence of pH and phosphate concentration on the phosphate binding capacity of five contemporary binders. An in vitro study.
Topics: Acetates; Calcium Carbonate; Calcium Compounds; Chelating Agents; Drug Combinations; Ferric Compounds; Hydrogen-Ion Concentration; Kinetics; Lanthanum; Magnesium; Phosphates; Sevelamer; Sucrose | 2019 |
Real-World Scenario Improvements in Serum Phosphorus Levels and Pill Burden in Peritoneal Dialysis Patients Treated with Sucroferric Oxyhydroxide.
Topics: Adult; Aged; Drug Combinations; Female; Ferric Compounds; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Male; Middle Aged; Peritoneal Dialysis; Phosphorus; Retrospective Studies; Sucrose | 2018 |
Sucroferric oxyhydroxide decreases serum phosphorus level and fibroblast growth factor 23 and improves renal anemia in hemodialysis patients.
Topics: Aged; Anemia; Demography; Drug Combinations; Female; Ferric Compounds; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Male; Phosphates; Renal Dialysis; Sucrose; Treatment Outcome | 2018 |
Phosphate Binders Derived from Natural Ores Contain Many Kinds of Metallic Elements Besides Their Active Ingredient Metals.
Topics: Calcium Carbonate; Chelating Agents; Drug Combinations; Ferric Compounds; Japan; Lanthanum; Metals; Phosphates; Polyamines; Sevelamer; Spectrophotometry, Atomic; Sucrose | 2018 |
[Short-term effects with sucroferric oxyhydroxide in hemodialysis patients: Experience in NephroCare France].
Topics: Aged; Cohort Studies; Drug Combinations; Female; Ferric Compounds; Ferritins; France; Humans; Hyperphosphatemia; Male; Middle Aged; Renal Dialysis; Retrospective Studies; Sucrose | 2019 |
One-Year Historical Cohort Study of the Phosphate Binder Sucroferric Oxyhydroxide in Patients on Maintenance Hemodialysis.
Topics: Adult; Aged; Chelating Agents; Cohort Studies; Drug Combinations; Female; Ferric Compounds; Humans; Hyperphosphatemia; Male; Medication Adherence; Middle Aged; Nutritional Status; Phosphates; Phosphorus; Renal Dialysis; Renal Insufficiency; Sucrose; Time Factors; Treatment Outcome | 2019 |
Phosphate binding by sucroferric oxyhydroxide ameliorates renal injury in the remnant kidney model.
Topics: Animals; Biomarkers; Biopsy; Disease Models, Animal; Disease Susceptibility; Drug Combinations; Ferric Compounds; Glomerulosclerosis, Focal Segmental; Immunohistochemistry; Male; Phosphates; Podocytes; Rats; Renal Insufficiency, Chronic; Sucrose | 2019 |
Changes in serum albumin and other nutritional markers when using sucroferric oxyhydroxide as phosphate binder among hemodialysis patients: a historical cohort study.
Topics: Cohort Studies; Creatinine; Dietary Proteins; Drug Combinations; Drug Substitution; Female; Ferric Compounds; Humans; Hypoalbuminemia; Male; Middle Aged; Parathyroid Hormone; Phosphates; Phosphorus; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies; Serum Albumin; Sucrose | 2019 |
A comparison between the combined effect of calcium carbonate with sucroferric oxyhydroxide and other phosphate binders: an in vitro and in vivo experimental study.
Topics: Animals; Calcium Carbonate; Drug Combinations; Ferric Compounds; Male; Phosphates; Rats; Rats, Sprague-Dawley; Sucrose | 2019 |
Chronic Therapy with Sucroferric Oxyhydroxide Does Not Affect Iron and Anemia Markers in Dialysis Patients.
Topics: Aged; Aged, 80 and over; Anemia; Biomarkers; Drug Combinations; Female; Ferric Compounds; Ferritins; Humans; Hyperphosphatemia; Iron; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis; Sucrose | 2020 |
Eosinophilic peritonitis induced by sucroferric oxyhydroxide.
Topics: Drug Combinations; Eosinophilia; Female; Ferric Compounds; Humans; Hyperphosphatemia; Kidney; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Peritonitis; Sucrose | 2020 |
Iron kinetics following treatment with sucroferric oxyhydroxide or ferric citrate in healthy rats and models of anaemia, iron overload or inflammation.
Topics: Administration, Oral; Anemia; Animals; Drug Combinations; Female; Ferric Compounds; Inflammation; Iron; Iron Overload; Kinetics; Male; Rats; Rats, Sprague-Dawley; Rats, Wistar; Sucrose; Tissue Distribution | 2020 |
Effect of sucroferric oxyhydroxide on gastrointestinal microbiome and uremic toxins in patients with chronic kidney disease undergoing hemodialysis.
Topics: Aged; Aged, 80 and over; Case-Control Studies; Cresols; Drug Combinations; Dysbiosis; Feces; Ferric Compounds; Gastrointestinal Microbiome; Humans; Indican; Middle Aged; Renal Dialysis; Renal Insufficiency, Chronic; Sucrose; Sulfuric Acid Esters | 2020 |
Renoprotective effects of sucroferric oxyhydroxide in a rat model of chronic renal failure.
Topics: Animals; Disease Models, Animal; Drug Combinations; Ferric Compounds; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Kidney Failure, Chronic; Male; Phosphorus; Rats; Rats, Wistar; Sucrose; Vascular Calcification | 2020 |
The real-world effectiveness of sucroferric oxyhydroxide in European hemodialysis patients: a 1-year retrospective database analysis.
Topics: Aged; Chelating Agents; Databases, Factual; Drug Combinations; Europe; Female; Ferric Compounds; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis; Sucrose | 2020 |
Long-term efficacy and safety of iron-based phosphate binders, ferric citrate hydrate and sucroferric oxyhydroxide, in hemodialysis patients.
Topics: Drug Combinations; Ferric Compounds; Humans; Hyperphosphatemia; Iron; Phosphates; Renal Dialysis; Retrospective Studies; Sucrose | 2022 |
Impact of sucroferric oxyhydroxide on the oral and intestinal microbiome in hemodialysis patients.
Topics: Drug Combinations; Ferric Compounds; Gastrointestinal Microbiome; Humans; Iron; Phosphates; Renal Dialysis; RNA, Ribosomal, 16S; Sucrose | 2022 |
A 6-Month clinical practice pilot study of sucroferric oxyhydroxide on nutritional status in patients on peritoneal dialysis.
Topics: Adult; Aged; Drug Combinations; Ferric Compounds; Humans; Hyperphosphatemia; Hypoalbuminemia; Middle Aged; Nutritional Status; Peritoneal Dialysis; Phosphates; Phosphorus; Pilot Projects; Prospective Studies; Serum Albumin; Sucrose | 2022 |
Decreased Clinical Toxicity and Two-Phase Elimination Kinetics Observed After Intravenous Iron Sucrose Overdose.
Topics: Adult; Drug Overdose; Female; Ferric Oxide, Saccharated; Humans; Iron; Substance-Related Disorders; Sucrose; Young Adult | 2022 |